Uptake and metabolism of lipoproteins from patients with diabetes mellitus type II by glomerular epithelial cells

Nephrology Dialysis Transplantation

Volumn 12, Issue 7, 1997, Pages 1336-1343

  Kramer Guth A ^a   Quaschning, T ^a   Pavenstadt H ^a   Galle, J ^a   Nauck, M ^a   Baumstark, M W ^a   Schollmeyer, P ^a   Marz W ^a   Wanner, C ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Atherosclerosis; Glomerulosclerosis; Glycation; LDL receptor; Modified LDL

Indexed keywords

CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DYSLIPIDEMIA; ELECTROPHORETIC MOBILITY; FEMALE; GLOMERULUS EPITHELIUM; GLYCATION; HOMEOSTASIS; HUMAN; HUMAN CELL; ISOTOPE LABELING; KIDNEY FUNCTION; LIPID TRANSPORT; LIPOPROTEIN METABOLISM; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN ISOLATION; PROTEIN TRANSPORT; RECEPTOR AFFINITY; STEROL SYNTHESIS;

AGED; CELLS, CULTURED; CHOLESTEROL ESTERS; DIABETES MELLITUS, TYPE 2; EPITHELIUM; FEMALE; HUMANS; KIDNEY GLOMERULUS; LIPIDS; LIPOPROTEINS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; RECEPTORS, LDL; STEROLS;

EID: 0030836458     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/12.7.1336     Document Type: Article

References (45)

1. Lippert J, Ritz E, Schwarzbeck A, Schneider P. The rising tide of endstage renal failure from diabetic nephropathy type II - an epidemiological analysis. Nephrol Dial Transplant 1995; 10: 462-467
2. Mulec H, Johnson SA, Björck S. Relation between serum cholesterol and diabetic nephropathy. Lancet 1993; 335: 1537-1538
3. Samuelson O, Aurell M, Knight-Gibson C, Alaupovic P, Attman P-O. Apolipoprotein-B- containing lipoproteins and the progression of renal insufficiency. Nephron 1993; 63: 279-285
4. Mulec H, Johnson SA, Wiklund O, Björck S. Cholesterol: A renal risk factor in diabetic nephropathy. Am J Kidney Dis 1993; 22: 196-201
5. Lam KSL, Cheng IKP, Janus ED, Pang RWC. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 1995; 38: 604-609
6. Taskinen MR. Quantitative and qualitative lipoprotein abnormalities in diabetes mellitus. Diabetes 1992; 41 [Suppl 2]: 12-17
7. Kasiske BL, Cleary MP, Keane WF. Effects of genetic obesity on renal structure and function in the Zucker rat. J Lab Clin Med 1985; 106: 98-604
8. Roullef JB, Lacour B, Yvert JP, Pratt JJ, Drucke T. Factors of increase in serum triglyceride-rich lipoproteins in uremic rats. Kidney Int 1985; 27: 420-425
9. Keane WF, Kasiske BL, O'Donnel MP. Lipids and progressive glomerulosclerosis: a model analogous to atherosclerosis. Am J Nephrol 1988; 8: 261-271
10. Gröne HJ, Walli AK, Gröne E, Krämer A, Clemens MR, Seidel D. Receptor mediated uptake of apoE and apoB rich lipoproteins by human glomerular epithelial cells. Kidney Int 1990; 37: 1449-1459
11. Krämer A, Nauck M, Pavenstädt H et al. Receptor mediated uptake of IDL and LDL from nephrotic patients by glomerular epithelial cells. Kidney Int 1993; 44: 1341-1351
12. Coritsidis G, Rifici V, Gupta S et al. Preferential binding of oxidized LDL to rat glomeruli in vivo and cultured mesangial cells in vitro. Kidney Int 1991; 39 858-866
13. Wheeler DC, Ravinder SC, Topley N, Peterson MM, Davies M, Williams JD. Oxidation of low density lipoprotein by mesangial cells may promote glomerular injury. Kidney Int 1994; 45: 1628-1636
14. Hiramatsu K, Bierman EL, Chait A. Metabolism of low density lipoprotein from patients with diabetic hypertriglyceridemia by cultured human skin fibroblasts. Diabetes 1985; 34: 8-14
15. Lopes-Virella MF, Shere G, Lees AM et al. Surface binding, internalization and degradation by cultured human fibroblasts of LDL isolated from type I diabetic patients: changes with metabolic control. Diabetologia 1982; 22: 430-436
16. Gilbert SF, Migeon R. D-valine as a selective agent for normal human and rodent epithelial cells in culture. Cell 1975; 5: 11-17
17. Kreisberg JI, Karnowski MJ. Glomerular cells in culture. Kidney Int 1983; 23: 439-447
18. Bross KJ, Pangalis GA, Staatz CG, Blume KG. Demonstration of cell surface antigens and their antibodies by the peroxidase-antiperoxidase method. Transplantation 1978; 25: 331-334
19. Manual of Laboratory Operation. Lipid Research Clinics Program. DHEW No (NIH) 75-628 Bethesda, National Heart and Lung Institute, 1971; 1-74
20. Wanner C, Hörl WH, Luley C, Wieland H. Effect of HMG-CoA reductase inhibitors in hypercholesterolemic patients on hemodialysis. Kidney Int 1991; 39: 754-760
21. Luley C, Baumstark MW, Wieland H. Rapid apolipoproteinE phenotyping by immunofixation in agarose. J Lipid Res 1991; 32: 880-883
22. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human plasma. J Clin Invest 1955; 34: 1345-1353
23. Lindgren FT. Preparative ultracentrifuge laboratory procedures and suggestions for lipoprotein analysis. In: Perkins EG (ed.). Analysis of lipids and lipoproteins. American Oil Chemists' Society. Champaign. IL.; 204-224
24. Baumstark MW, Kreutz W, Berg A, Frey I, Keul J. Structure of human low-density lipoprotein subfractions determined by X-ray small-angle scattering. Biochim Biophys Acta 1990; 1037: 48-57
25. Steinbrecher UP, Witztum JL, Partharasathy S, Steinberg D. Decrease in reactive amino groups during oxidation or endothelial cell modification of LDL: correlations with changes in receptor mediated catabolism. Arteriosclerosis 1987; 7: 135-143
26. Ohkawa H, Ohishi N, Yagi M. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95: 351-358
27. McFarlane AS. Efficient trace labelling of proteins with iodine. Nature 1958; 182: 53-56
28. Bilheimer DW, Eisenberg S, Levy RI. The metabolism of very low density lipoprotein proteins. I. preliminary in vitro and in vivo observations. Biochem Biophys Acta 1972; 260: 212-221
29. Krämer-Guth A, Nauck M, Pavenstädt H et al. Preferential uptake of intermediate-density lipoproteins from nephrotic patients by human mesangial and liver cells. J Am Soc Nephrol 1994; 5: 1081-1090
30. Goldstein JL, Basu JK, Brown US. Receptor-mediated endocytosis of low density lipoprotein in cultured cells. In: Fischer S, Fleischer B (ed.). Methods in Enzymology (Vol. 98). Academic Press Inc, New York, 1983; 241-260
31. Davignon J, Gregg RE, Suig GF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1988, 8: 1-21
32. Gupta S, Rifici V, Crowley S, Brownlee M, Shan Z, Schlondorff D. Interaction of LDL and modified LDL with mesangial cells and matrix. Kidney Int 1992; 1161-1169
33. Kerjaschki D. Dysfunction of cell biological mechanisms of visceral epithelial cell (podocytes) in glomerular diseases. Kidney Int 1994; 45: 300-313
34. Kriz W, Elger M, Nagata M et al. The role of podocytes in the development of glomerular sclerosis. Kidney Int 1994; 45 [Suppl 42]: S64-S72
35. Triau JE, Arbetter J, Schäfer EJ. Impaired hepatocyte binding, uptake and degradation of glyosylated low density lipoproteins. Biochim Biophys Acta 1986; 877: 359-365
36. Sasaki J, Cottam GL. Glycosylation of LDL decreases its ability to interact with high affinity receptors of human fibroblasts in vitro and decreases its clearance from rabbit plasma in vivo. Biochim Biophys Acta 1982; 713: 199-207
37. Schleicher E, Wieland OH. Specific quantitation by HPLC of protein (lysine) bound glucose in human serum albumin and other glycated proteins. J Clin Chem Clin Biochem 1981; 19: 81-87
38. Gonen B, Goldberg AP, Harter HR, Schonfeld G. Abnormal cell-interactive properties of low density lipoproteins isolated from patients with chronic renal failure. Metabolism 1985; 34: 10-15
39. Steinbrecher UP, Witztum JL. Glycosylation of LDL to an extent comparable to that seen in diabetes slows their catabolism. Diabetes 1984; 33: 130-134
40. Manzato E, Zambon A, Lapolla A et al. Lipoprotein abnormalities in well treated type II diabetic patients. Diabetes Care 1993; 16: 469-475
41. Galeano NF, Milne R, Marcel YL et al. Apoprotein-B structure and receptor recognition of triglyceride rich low density lipoprotein (LDL) is modified in small LDL but not in triglyceride rich LDL of normal size. J Biol Chem 1993; 269: 511-519
42. DeGraaf J, Hak-Lemmers HLM, Hectors MPC, Demacker PNM, Hendriks JCM, Stalenhoef AFH. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arteriosclerosis 1991; 11: 298-306
43. DeJager S, Bruckert E, Chapman MJ. Dense low density lipoprotein subspecies with diminished oxidative resistance predominate in combined hyperlipidemia. J Lipid Res 1993; 34: 295-302
44. Nigon F, Lesnik P, Rouis M, Chapman MJ. Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor. J Lipid Res 1991; 32: 1741-1753
45. Krämer-Guth A, Greiber S, Pavenstädt H et al. Interaction of native and oxidized lipoprotein (a) with human mesangial cells and matrix. Kidney Int 1996, 49: 1250-1261